Usefulness of vonoprazan,a potassium ion-competitive acid blocker,for primary eradication of Helicobacter pylori

被引:8
|
作者
Shinya Yamada [1 ]
Takumi Kawakami [1 ]
Yoshikazu Nakatsugawa [1 ]
Takahiro Suzuki [1 ]
Hideki Fujii [1 ]
Naoya Tomatsuri [1 ]
Hideki Nakamura [1 ]
Hideki Sato [1 ]
Yusuke Okuyama [1 ]
Hiroyuki Kimura [1 ]
Norimasa Yoshida [1 ]
机构
[1] Department of Gastroenterology,Japanese Red Cross Kyoto Daiichi Hospital
关键词
Helicobacter pylori; Eradication; Vonoprazan; Chronic gastritis; Potassium ion-competitive acid blocker;
D O I
暂无
中图分类号
R573 [胃疾病];
学科分类号
1002 ; 100201 ;
摘要
AIM To investigate usefulness of triple therapy with vonoprazan,a potassium ion-competitive acid blocker and antibiotics,for Helicobacter pylori(H.pylori) eradication.METHODS The H.pylori eradication rate was examined in 2507 patients(2055 undergoing primary eradication and 452 undergoing secondary eradication,excluding patients with subtotal gastrectomy) at the Japanese Red Cross Kyoto Daiichi Hospital from March 2013 to September 2015.For patients treated from March 2013 to February 2015,a proton pump inhibitor(PPI) was used to reduce acid secretion,while vonoprazan was used after March 2015.The success rates of the 2 regimens(PPI + amoxicillin + clarithromycin/metronidazole,or vonoprazan + amoxicillin + clarithromycin/metronidazole) were compared.RESULTS The success rate of primary H.pylori eradication was significantly higher in the vonoprazan group.When stratified by the underlying disease,a significant increase of the H.pylori eradication rate was observed in patients with chronic gastritis.A significantly lower H.pylori eradication rate was observed in younger patients compared to older patients in the PPI group,but there was no difference according to age in the vonoprazan group.On the otherhand,the success rate of secondary eradication was similar at approximately 90% in both groups.CONCLUSION Vonoprazan is very useful for primary eradication of H.pylori,and may become a first-line acid secretion inhibitor instead of PPIs.
引用
收藏
页码:550 / 555
页数:6
相关论文
共 50 条
  • [31] Quantitative and qualitative usefulness of rebamipide in eradication regimen of Helicobacter pylori
    Hahm, KB
    Lee, KJ
    Kim, YS
    Kim, JH
    Cho, SW
    Yim, H
    Joo, HJ
    DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (09) : 192S - 197S
  • [32] Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication
    Hu, Yi
    Xu, Xin
    Ouyang, Yao-Bin
    He, Cong
    Li, Nian-Shuang
    Xie, Chuan
    Peng, Chao
    Zhu, Zhen-Hua
    Xie, Yong
    Shu, Xu
    Lu, Nong-Hua
    Zhu, Yin
    HELICOBACTER, 2022, 27 (05)
  • [33] Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori
    Li, Min
    Oshima, Tadayuki
    Horikawa, Tomoki
    Tozawa, Katsuyuki
    Tomita, Toshihiko
    Fukui, Hirokazu
    Watari, Jiro
    Miwa, Hiroto
    HELICOBACTER, 2018, 23 (04)
  • [34] Eradication rate and safety of vonoprazan-amoxicillin dual therapy for helicobacter pylori eradication: a randomized controlled trial
    Jiang, Guoping
    Luo, Mengzhao
    Zheng, Peifen
    Cong, Yanqun
    Feng, Yuliang
    Zhou, Feng
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2024, 59 (11) : 1229 - 1233
  • [35] Meta-analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy
    Yang, Hui
    Zhang, Miao
    Ma, Gang
    Yang, Jiaqi
    Wang, Kemei
    Jiang, Shuangshuang
    Dong, Jiaqiang
    Han, Ying
    HELICOBACTER, 2024, 29 (02)
  • [36] Efficacy and Safety of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors as Helicobacter pylori Eradication Therapy: A Meta-Analysis of Randomized Clinical Trials
    Shah, Abdullah
    Usman, Omer
    Zahra, Tafseer
    Chaudhari, Sandipkumar S.
    Mulaka, Gopi Sairam Reddy
    Masood, Rumaisa
    Batool, Saima
    Saleem, Faraz
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [37] Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence
    Akazawa, Yuko
    Fukuda, Daisuke
    Fukuda, Yutaka
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (06) : 845 - 852
  • [38] Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility
    Hidetaka Okubo
    Junichi Akiyama
    Masao Kobayakawa
    Megumi Kawazoe
    Saori Mishima
    Yusuke Takasaki
    Naoyoshi Nagata
    Takayuki Shimada
    Chizu Yokoi
    Shiori Komori
    Kana Kimura
    Yuya Hisada
    Eri Iwata
    Kazuhiro Watanabe
    Naohiro Yanagisawa
    Sho Shiroma
    Akira Shimomura
    Koki Okahara
    Hourin Cho
    Naomi Uemura
    Journal of Gastroenterology, 2020, 55 : 1054 - 1061
  • [39] A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori
    Yang, Faming
    Yu, Baiyang
    Qin, Lang
    Dai, Xiaorong
    MEDICINE, 2023, 102 (41) : E35610
  • [40] The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations
    Echizen, Hirotoshi
    CLINICAL PHARMACOKINETICS, 2016, 55 (04) : 409 - 418